Video
Author(s):
Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Revisit the OncLive On Air Episodes From February 2024
Eckfeldt Looks Towards the Future of AML and MDS Care
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL
State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth